NASDAQ:GANX Gain Therapeutics Q3 2026 Earnings Results & Report $1.07 -0.02 (-1.83%) As of 02:16 PM Eastern This is a fair market value price provided by Massive. Learn more. Gain Therapeutics beat analyst earnings expectations in its Q3 2026 results, released November 10, 2026. The company reported EPS of -$0.07 versus the -$0.13 consensus estimate. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ3 2026Report DateNovember 10, 2026TimeBefore Market Opens Gain Therapeutics EPS ResultsActual EPS-$0.07Consensus EPS -$0.13Beat/MissBeat by +$0.06One Year Ago EPSN/AEPS Beat Rate4 of last 8 quartersGain Therapeutics Revenue ResultsActual RevenueN/AExpected Revenue$33 thousandBeat/MissN/AYoY Revenue GrowthN/AUpcoming EarningsGain Therapeutics' Q3 2026 earnings is estimated for Wednesday, November 11, 2026, based on past reporting schedulesConference Call ResourcesEarnings HistoryCompany Profile Gain Therapeutics Q3 2026 Earnings FAQ Did Gain Therapeutics beat earnings estimates for Q3 2026? Gain Therapeutics (NASDAQ:GANX) reported earnings of -$0.07 per share for Q3 2026, beating the consensus estimate of -$0.13. The report was announced on Tuesday, November 10, 2026. When is Gain Therapeutics' next earnings date? Gain Therapeutics' next earnings date is estimated for Wednesday, November 11, 2026. MarketBeat tracks confirmed and estimated earnings dates for Gain Therapeutics on the company's earnings history page. Gain Therapeutics Earnings HeadlinesGain Therapeutics Reports Financial Results for Third Quarter 2026 and Provides Corporate UpdateNovember 10 at 7:00 AM | globenewswire.comGain Therapeutics (GANX) Projected to Announce Earnings on WednesdayNovember 10 at 2:26 AM | americanbankingnews.comThe Withdrawal You'll Never See on Your StatementA proposal circulating in Washington, dubbed the Mar-a-Lago Accord, calls for tariffs and currency pressure to deliberately weaken the US dollar, making American exports cheaper. For savers, a weaker dollar can quietly reduce purchasing power even if account balances stay the same. Bishop Gold Group's free 2026 Gold IRA Guide explains how physical gold can be held inside a retirement account, including a common rollover mistake that can trigger a taxable distribution.November 10 at 1:00 AM | Bishop Gold Group (Ad)Gain Therapeutics Announces Late-Breakers and Poster Presentations at Upcoming Scientific ConferencesNovember 5, 2026 | globenewswire.comSibylla Biotech Appoints Usman Azam CEO, Gianluca Fuggetta CFO, and Expands Executive Team to Drive Transition to ClinicOctober 13, 2026 | globenewswire.comGain Therapeutics to Attend the 2026 Maxim Growth SummitOctober 8, 2026 | globenewswire.comSee More Gain Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Gain Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Gain Therapeutics and other key companies, straight to your email. Email Address About Gain TherapeuticsGain Therapeutics (NASDAQ:GANX) is a biotechnology company focused on developing small-molecule therapies for diseases associated with lysosomal dysfunction, including neurodegenerative and rare disorders. The company’s approach is designed to identify compounds that bind to and modulate disease-related proteins, with the goal of restoring their function and addressing underlying disease mechanisms. Gain Therapeutics’ lead investigational program, GT-02287, is an orally administered, brain-penetrant small molecule being developed for GBA1-associated Parkinson’s disease. The program is intended to activate or stabilize glucocerebrosidase, an enzyme whose impaired function is linked to a genetic subset of Parkinson’s disease and other lysosomal disorders. GT-02287 remains an investigational product and has not been approved for commercial use. The company uses its proprietary allosteric small-molecule discovery platform to pursue additional treatments for central nervous system and lysosomal diseases. Gain Therapeutics is headquartered in Bethesda, Maryland, and its programs are being advanced through clinical and preclinical development for potential use in patients in international markets.View Gain Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles DraftKings Just Lost 20%—And Its Biggest Gamble Is Still AheadBarrick's Earnings Beat Could Be Overshadowed by an Even Bigger OpportunityAxon vs. Motorola: Which Public Safety Stock Has More Upside After Q3 Earnings?Oklo Changes the Narrative: Does a Nuclear Stock Price Explosion Come Next?Wall Street May Be Making a Big Mistake With monday.com StockCloudflare's 20% Sell-Off May Have Created an Opening for InvestorsMarketBeat Week in Review – 11/2 - 11/6 Upcoming Earnings Brookfield (11/12/2026)NU (11/12/2026)Applied Materials (11/12/2026)Cisco Systems (11/12/2026)Mizuho Financial Group (11/13/2026)Mitsubishi UFJ Financial Group (11/13/2026)Sumitomo Mitsui Financial Group (11/13/2026)Home Depot (11/17/2026)Walt Disney (11/17/2026)NVIDIA (11/17/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
